Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review
The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to thera...
Gespeichert in:
Veröffentlicht in: | European journal of cancer & clinical oncology 1982-12, Vol.18 (12), p.1229-1235 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1235 |
---|---|
container_issue | 12 |
container_start_page | 1229 |
container_title | European journal of cancer & clinical oncology |
container_volume | 18 |
creator | Ellims, Peter H. Gan, T.Eng Medley, Gabriele |
description | The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness. |
doi_str_mv | 10.1016/0277-5379(82)90123-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80304375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537982901237</els_id><sourcerecordid>80304375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c354c2f28d98ca8d698d183f4e763cfbd0368e421223e23cded50e55d78757673</originalsourceid><addsrcrecordid>eNp9kE9PAyEQxTloaq1-A004GT2ssrAsrAeTpvFf0sSLnskWZi3KLhW6Nf32srbx6AUmzJvHvB9CZzm5zkle3hAqRMaZqC4lvapITlkmDtD47_kIHcf4QQiVBWcjNCpFSRmhY2RmznZW1w4HcLCpOw3YN7itwyeEOJQanMOr4J1tINRr6ztsO7zs27rDbtuult6apHf2vUvTFuItnmLtUxkhmW4sfJ-gw6Z2EU739wS9Pdy_zp6y-cvj82w6zzTjYj2chaYNlaaSupamrKTJJWsKECXTzcIQVkooaE4pA8q0AcMJcG6EFFyUgk3Qxc43rfvVQ1yr1sZh_7oD30clCSMFEzwJi51QBx9jgEatgk2ZtyonagCqBnJqIKckVb9A1eB_vvfvFy2Yv6E9zdS_2_UhhUzBg4oJSEJqbAC9Vsbb_z_4ARUKh4o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80304375</pqid></control><display><type>article</type><title>Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ellims, Peter H. ; Gan, T.Eng ; Medley, Gabriele</creator><creatorcontrib>Ellims, Peter H. ; Gan, T.Eng ; Medley, Gabriele</creatorcontrib><description>The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness.</description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(82)90123-7</identifier><identifier>PMID: 6762302</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Carbon Radioisotopes ; Cell Division ; Child ; DNA, Neoplasm - biosynthesis ; Flow Cytometry ; Humans ; Lymphoma - metabolism ; Lymphoma - pathology ; Lymphoma - therapy ; Thymidine - metabolism ; Thymidine Kinase - metabolism ; Tritium</subject><ispartof>European journal of cancer & clinical oncology, 1982-12, Vol.18 (12), p.1229-1235</ispartof><rights>1982</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-c354c2f28d98ca8d698d183f4e763cfbd0368e421223e23cded50e55d78757673</citedby><cites>FETCH-LOGICAL-c357t-c354c2f28d98ca8d698d183f4e763cfbd0368e421223e23cded50e55d78757673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6762302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ellims, Peter H.</creatorcontrib><creatorcontrib>Gan, T.Eng</creatorcontrib><creatorcontrib>Medley, Gabriele</creatorcontrib><title>Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description>The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness.</description><subject>Adult</subject><subject>Carbon Radioisotopes</subject><subject>Cell Division</subject><subject>Child</subject><subject>DNA, Neoplasm - biosynthesis</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Lymphoma - metabolism</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Thymidine - metabolism</subject><subject>Thymidine Kinase - metabolism</subject><subject>Tritium</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9PAyEQxTloaq1-A004GT2ssrAsrAeTpvFf0sSLnskWZi3KLhW6Nf32srbx6AUmzJvHvB9CZzm5zkle3hAqRMaZqC4lvapITlkmDtD47_kIHcf4QQiVBWcjNCpFSRmhY2RmznZW1w4HcLCpOw3YN7itwyeEOJQanMOr4J1tINRr6ztsO7zs27rDbtuult6apHf2vUvTFuItnmLtUxkhmW4sfJ-gw6Z2EU739wS9Pdy_zp6y-cvj82w6zzTjYj2chaYNlaaSupamrKTJJWsKECXTzcIQVkooaE4pA8q0AcMJcG6EFFyUgk3Qxc43rfvVQ1yr1sZh_7oD30clCSMFEzwJi51QBx9jgEatgk2ZtyonagCqBnJqIKckVb9A1eB_vvfvFy2Yv6E9zdS_2_UhhUzBg4oJSEJqbAC9Vsbb_z_4ARUKh4o</recordid><startdate>198212</startdate><enddate>198212</enddate><creator>Ellims, Peter H.</creator><creator>Gan, T.Eng</creator><creator>Medley, Gabriele</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198212</creationdate><title>Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review</title><author>Ellims, Peter H. ; Gan, T.Eng ; Medley, Gabriele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c354c2f28d98ca8d698d183f4e763cfbd0368e421223e23cded50e55d78757673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adult</topic><topic>Carbon Radioisotopes</topic><topic>Cell Division</topic><topic>Child</topic><topic>DNA, Neoplasm - biosynthesis</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Lymphoma - metabolism</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Thymidine - metabolism</topic><topic>Thymidine Kinase - metabolism</topic><topic>Tritium</topic><toplevel>online_resources</toplevel><creatorcontrib>Ellims, Peter H.</creatorcontrib><creatorcontrib>Gan, T.Eng</creatorcontrib><creatorcontrib>Medley, Gabriele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ellims, Peter H.</au><au>Gan, T.Eng</au><au>Medley, Gabriele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1982-12</date><risdate>1982</risdate><volume>18</volume><issue>12</issue><spage>1229</spage><epage>1235</epage><pages>1229-1235</pages><issn>0277-5379</issn><abstract>The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>6762302</pmid><doi>10.1016/0277-5379(82)90123-7</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0277-5379 |
ispartof | European journal of cancer & clinical oncology, 1982-12, Vol.18 (12), p.1229-1235 |
issn | 0277-5379 |
language | eng |
recordid | cdi_proquest_miscellaneous_80304375 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adult Carbon Radioisotopes Cell Division Child DNA, Neoplasm - biosynthesis Flow Cytometry Humans Lymphoma - metabolism Lymphoma - pathology Lymphoma - therapy Thymidine - metabolism Thymidine Kinase - metabolism Tritium |
title | Clinical relevance of markers of cell proliferation in human lymphoid malignancies: A concise review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A30%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20relevance%20of%20markers%20of%20cell%20proliferation%20in%20human%20lymphoid%20malignancies:%20A%20concise%20review&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Ellims,%20Peter%20H.&rft.date=1982-12&rft.volume=18&rft.issue=12&rft.spage=1229&rft.epage=1235&rft.pages=1229-1235&rft.issn=0277-5379&rft_id=info:doi/10.1016/0277-5379(82)90123-7&rft_dat=%3Cproquest_cross%3E80304375%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80304375&rft_id=info:pmid/6762302&rft_els_id=0277537982901237&rfr_iscdi=true |